Trial Profile
A Randomized, Placebo-controlled, Patient and Investigator Blinded, Study Investigating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Doses of CFZ533 in Patients With Moderately Active Proliferative Lupus Nephritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Iscalimab (Primary)
- Indications Lupus nephritis; Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 26 Jul 2023 Status changed from active, no longer recruiting to completed.
- 25 Apr 2023 Planned End Date changed from 10 Jul 2023 to 3 Jul 2023.
- 25 Apr 2023 Planned primary completion date changed from 10 Jul 2023 to 3 Jul 2023.